Skip to main content
. 2011 Apr 12;104(10):1594–1601. doi: 10.1038/bjc.2011.129

Figure 6.

Figure 6

Relation of TS expression level to tumour response in NSCLC patients treated with pemetrexed and either carboplatin or cisplatin. (A) Representative sections of carcinomas including cells with the indicated intensities of TS immunostaining. Scale bars, 125 μm. (B) TS expression level (HSCORE) for the clinical specimens of 24 patients classified according to tumour response (response=CR or PR, n=7; non-response=SD or PD, n=17). Horizontal lines indicate mean values. The P value was determined by Student's two-tailed t test. (C) Progression-free survival of the NSCLC patients according to the expression level of TS in tumour specimens. The P-value was determined with the log-rank test.